Reliability of White Matter Microstructural Changes in HIV Infection: Meta-Analysis and Confirmation

REFERENCES

1. 1.↵
   2. Lima VD,
   3. Hogg RS,
   4. Harrigan PR, et al

   . Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21:685–92 doi:10.1097/QAD.0b013e32802ef30c pmid:17413689

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Hammer SM,
   3. Squires KE,
   4. Hughes MD, et al

   . A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725–33 doi:10.1056/NEJM199709113371101 pmid:9287227

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Simioni S,
   3. Cavassini M,
   4. Annoni JM, et al

   . Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243–50 doi:10.1097/QAD.0b013e3283354a7b pmid:19996937

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Cohen RA,
   3. Boland R,
   4. Paul R, et al

   . Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS 2001;15:341–45 doi:10.1097/00002030-200102160-00007 pmid:11273214

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Cysique LA,
   3. Maruff P,
   4. Brew BJ

   . Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus–infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts clinical report. J Neurovirol 2004;10:350–57 doi:10.1080/13550280490521078 pmid:15765806

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Giancola ML,
   3. Lorenzini P,
   4. Balestra P, et al

   . Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006;41:332–37 doi:10.1097/01.qai.0000197077.64021.07 pmid:16540934

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Tozzi V,
   3. Balestra P,
   4. Bellagamba R, et al

   . Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174–82 doi:10.1097/QAI.0b013e318042e1ee pmid:17356465

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Maki PM,
   3. Rubin LH,
   4. Valcour V, et al

   . Cognitive function in women with HIV: findings from the Women's Interagency HIV Study. Neurology 2015;84:231–40 doi:10.1212/WNL.0000000000001151 pmid:25540304

   CrossRefPubMed
9. 9.↵
   2. Heaton RK,
   3. Franklin DR,
   4. Ellis RJ, et al

   . HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3–16 doi:10.1007/s13365-010-0006-1 pmid:21174240

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Gray F,
    3. Scaravilli F,
    4. Everall I, et al

    . Neuropathology of early HIV-1 infection. Brain Pathol 1996;6:1–15 doi:10.1111/j.1750-3639.1996.tb00775.x pmid:8866743

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Jellinger K,
    3. Setinek U,
    4. Drlicek M, et al

    . Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol 2000;100:213–20 doi:10.1007/s004010000245 pmid:10963370

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Chan P,
    3. Brew BJ

    . HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep 2014;11:317–24 doi:10.1007/s11904-014-0221-0 pmid:24966139

    CrossRefPubMed
13. 13.↵
    2. Marra CM,
    3. Zhao Y,
    4. Clifford DB, et al

    ; AIDS Clinical Trials Group 736 Study Team. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23:1359–66 doi:10.1097/QAD.0b013e32832c4152 pmid:19424052

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Vitiello B,
    3. Goodkin K,
    4. Ashtana D, et al

    . HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people. AIDS 2007;21:1415–22 doi:10.1097/QAD.0b013e328220e71a pmid:17589187

    CrossRefPubMed
15. 15.↵
    2. Robertson KR,
    3. Smurzynski M,
    4. Parsons TD, et al

    . The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915–21 doi:10.1097/QAD.0b013e32828e4e27 pmid:17721099

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Cysique LA,
    3. Brew BJ

    . Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011;17:176–83 doi:10.1007/s13365-011-0021-x pmid:21416169

    CrossRefPubMed
17. 17.↵
    2. Cysique LA,
    3. Maruff P,
    4. Brew BJ

    . Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006;66:1447–50 doi:10.1212/01.wnl.0000210477.63851.d3 pmid:16682686

    Abstract/FREE Full Text
18. 18.↵
    2. Sevigny J,
    3. Albert S,
    4. McDermott M, et al

    . Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004;63:2084–90 doi:10.1212/01.WNL.0000145763.68284.15 pmid:15596754

    Abstract/FREE Full Text
19. 19.↵
    2. Grund B,
    3. Wright EJ,
    4. Brew BJ, et al

    ; INSIGHT SMART Study Group. Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. J Neurovirol 2013;19:383–92 doi:10.1007/s13365-013-0190-x pmid:23943468

    CrossRefPubMed
20. 20.↵
    2. Woods SP,
    3. Moore DJ,
    4. Weber E, et al

    . Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009;19:152–68 doi:10.1007/s11065-009-9102-5 pmid:19462243

    CrossRefPubMed
21. 21.↵
    2. Thurnher MM,
    3. Castillo M,
    4. Stadler A, et al

    . Diffusion-tensor MR imaging of the brain in human immunodeficiency virus–positive patients. AJNR Am J Neuroradiol 2005;26:2275–81 pmid:16219833

    Abstract/FREE Full Text
22. 22.↵
    2. Budka H

    . Human immunodeficiency virus (HIV)-induced disease of the central nervous system: pathology and implications for pathogenesis. Acta Neuropathol 1989;77:225–36 doi:10.1007/BF00687573 pmid:2538039

    CrossRefPubMed
23. 23.↵
    2. Leite SC,
    3. Corrêa DG,
    4. Doring TM, et al

    . Diffusion tensor MRI evaluation of the corona radiata, cingulate gyri, and corpus callosum in HIV patients. J Magn Reson Imaging 2013;38:1488–93 doi:10.1002/jmri.24129 pmid:23559497

    CrossRefPubMed
24. 24.↵
    2. Ragin AB,
    3. Wu Y,
    4. Gao Y, et al

    . Brain alterations within the first 100 days of HIV infection. Ann Clin Transl Neurol 2015;2:12–21 doi:10.1002/acn3.136 pmid:25642430

    CrossRefPubMed
25. 25.↵
    2. Kamat R,
    3. Brown GG,
    4. Bolden K, et al

    . Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection. J Clin Exp Neuropsychol 2014;36:854–66 doi:10.1080/13803395.2014.950636 pmid:25275424

    CrossRefPubMed
26. 26.↵
    2. Zhu T,
    3. Zhong J,
    4. Hu R, et al

    . Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study. J Neurovirol 2013;19:10–23 doi:10.1007/s13365-012-0135-9 pmid:23179680

    CrossRefPubMed
27. 27.↵
    2. Stubbe-Drger B,
    3. Deppe M,
    4. Mohammadi S, et al

    ; German Competence Network HIV/AIDS. Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study. BMC Neurol 2012;12:23 doi:10.1186/1471-2377-12-23 pmid:22548835

    CrossRefPubMed
28. 28.↵
    2. Hoare J,
    3. Fouche JP,
    4. Spottiswoode B, et al

    . White-matter damage in Clade C HIV-positive subjects: a diffusion tensor imaging study. J Neuropsychiatry Clin Neurosci 2011;23:308–15 doi:10.1176/jnp.23.3.jnp308 pmid:21948892

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Pfefferbaum A,
    3. Rosenbloom MJ,
    4. Adalsteinsson E, et al

    . Diffusion tensor imaging with quantitative fibre tracking in HIV infection and alcoholism comorbidity: synergistic white matter damage. Brain 2007;130:48–64 pmid:16959813

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Pomara N,
    3. Crandall DT,
    4. Choi SJ, et al

    . White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatry Res 2001;106:15–24 doi:10.1016/S0925-4927(00)00082-2 pmid:11231096

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Filippi CG,
    3. Ulug AM,
    4. Ryan E, et al

    . Diffusion tensor imaging of patients with HIV and normal-appearing white matter on MR images of the brain. AJNR Am J Neuroradiol 2001;22:277–83 pmid:11156769

    Abstract/FREE Full Text
32. 32.↵
    2. Wright PW,
    3. Vaida FF,
    4. Fernández RJ, et al

    . Cerebral white matter integrity during primary HIV infection. AIDS 2015;29:433–42 doi:10.1097/QAD.0000000000000560 pmid:25513818

    CrossRefPubMed
33. 33.↵
    2. Chang L,
    3. Wong V,
    4. Nakama H, et al

    . Greater than age-related changes in brain diffusion of HIV patients after 1 year. J Neuroimmune Pharmacol 2008;3:265–74 doi:10.1007/s11481-008-9120-8 pmid:18709469

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Wright P,
    3. Heaps J,
    4. Shimony JS, et al

    . The effects of HIV and combination antiretroviral therapy on white matter integrity. AIDS 2012;26:1501–08 doi:10.1097/QAD.0b013e3283550bec pmid:22546990

    CrossRefPubMed
35. 35.↵
    2. Seider TR,
    3. Gongvatana A,
    4. Woods AJ, et al

    . Age exacerbates HIV-associated white matter abnormalities. J Neurovirol 2016;22:201–12 doi:10.1007/s13365-015-0386-3 pmid:26446690

    CrossRefPubMed
36. 36.↵
    2. Schwarzer G,
    3. Carpenter JR,
    4. Rücker G

    . Meta-Analysis with R. New York: Springer-Verlag; 2015
37. 37.↵
    2. Higgins JP,
    3. Thompson SG,
    4. Deeks JJ, et al

    . Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60 doi:10.1136/bmj.327.7414.557 pmid:12958120

    FREE Full Text
38. 38.↵
    2. Higgins JP,
    3. Thompson SG

    . Controlling the risk of spurious findings from meta-regression. Stat Med 2004;23:1663–82 doi:10.1002/sim.1752 pmid:15160401

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Sacktor NC,
    3. Wong M,
    4. Nakasujja N, et al

    . The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367–74 pmid:16103767

    PubMedWeb of Science
40. 40.↵
    2. Brandt J

    . The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clinical Neuropsychologist 1991;5:125–42 doi:10.1080/13854049108403297

    CrossRef
41. 41.↵
    2. Robinson-Papp J,
    3. Byrd D,
    4. Mindt MR, et al

    ; Manhattan HIV Brain Bank. Motor function and human immunodeficiency virus–associated cognitive impairment in a highly active antiretroviral therapy–era cohort. Arch Neurol 2008;65:1096–101 doi:10.1001/archneur.65.8.1096 pmid:18695060

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Fahn S,
    2. Marsden CD,
    3. Goldstein M,
    4. Calne DB

    2. Fahn S,
    3. Elton RL

    , UPDRS program members. Unified Parkinsons Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinsons Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153–63
43. 43.↵
    2. Trites R

    . Grooved Pegboard Test. Lafayette: Lafayette Instrument; 1989
44. 44.↵
    2. Smith SM,
    3. Jenkinson M,
    4. Woolrich MW, et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208–19 doi:10.1016/j.neuroimage.2004.07.051 pmid:15501092

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Andersson JL,
    3. Jenkinson M,
    4. Smith S

    . Non-linear registration, aka Spatial normalisation FMRIB technical report TR07JA2. FMRIB Centre, Oxford, UK. June 28, 2007. https://www.fmrib.ox.ac.uk/datasets/techrep/tr07ja2/tr07ja2.pdf. Accessed May 2, 2017.
46. 46.↵
    2. Smith SM,
    3. Jenkinson M,
    4. Johansen-Berg H, et al

    . Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487–505 doi:10.1016/j.neuroimage.2006.02.024 pmid:16624579

    CrossRefPubMedWeb of Science
47. 47.↵
    2. Oishi K,
    3. Faria AV,
    4. van Zijl PC, et al

    . MRI Atlas of Human White Matter. Amsterdam: Academic Press; 2010
48. 48.↵
    2. Sexton CE,
    3. Walhovd KB,
    4. Storsve AB, et al

    . Accelerated changes in white matter microstructure during aging: a longitudinal diffusion tensor imaging study. J Neurosci 2014;34:15425–36 doi:10.1523/JNEUROSCI.0203-14.2014 pmid:25392509

    Abstract/FREE Full Text
49. 49.↵
    2. Broderick DF,
    3. Wippold FJ 2nd.,
    4. Clifford DB, et al

    . White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex. AJR Am J Roentgenol 1993;161:177–81 doi:10.2214/ajr.161.1.8517298 pmid:8517298

    CrossRefPubMed
50. 50.↵
    2. Jarvik JG,
    3. Hesselink JR,
    4. Kennedy C, et al

    . Acquired immunodeficiency syndrome: magnetic resonance patterns of brain involvement with pathologic correlation. Arch Neurol 1988;45:731–36 doi:10.1001/archneur.1988.00520310037014 pmid:3390027

    CrossRefPubMedWeb of Science
51. 51.↵
    2. Power C,
    3. Kong PA,
    4. Crawford TO, et al

    . Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 1993;34:339–50 doi:10.1002/ana.410340307 pmid:7689819

    CrossRefPubMedWeb of Science
52. 52.↵
    2. Chang L,
    3. Ernst T,
    4. Leonido-Yee M, et al

    . Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999;52:100–08 doi:10.1212/WNL.52.1.100 pmid:9921855

    Abstract/FREE Full Text
53. 53.↵
    2. Mohamed MA,
    3. Barker PB,
    4. Skolasky RL, et al

    . Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging 2010;28:1251–57 doi:10.1016/j.mri.2010.06.007 pmid:20688449

    CrossRefPubMedWeb of Science
54. 54.↵
    2. Cardenas VA,
    3. Meyerhoff DJ,
    4. Studholme C, et al

    . Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol 2009;15:324–33 doi:10.1080/13550280902973960 pmid:19499454

    CrossRefPubMedWeb of Science
55. 55.↵
    2. McArthur JC,
    3. Kumar AJ,
    4. Johnson DW, et al

    . Incidental white matter hyperintensities on magnetic resonance imaging in HIV-1 infection; multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1990;3:252–59 pmid:2406415

    PubMedWeb of Science
56. 56.↵
    2. Ragin AB,
    3. Wu Y,
    4. Storey P, et al

    . Diffusion tensor imaging of subcortical brain injury in patients infected with human immunodeficiency virus. J Neurovirol 2005;11:292–98 doi:10.1080/13550280590953799 pmid:16036809

    CrossRefPubMedWeb of Science
57. 57.↵
    2. Ragin A,
    3. Storey P,
    4. Cohen B, et al

    . Disease burden in HIV-associated cognitive impairment: a study of whole-brain imaging measures. Neurology 2004;63:2293–97 doi:10.1212/01.WNL.0000147477.44791.BD pmid:15623689

    Abstract/FREE Full Text
58. 58.↵
    2. Wang B,
    3. Liu Z,
    4. Liu J, et al

    . Gray and white matter alterations in early HIV-infected patients: combined voxel-based morphometry and tract-based spatial statistics. J Magn Reson Imaging 2016;43:1474–83 doi:10.1002/jmri.25100 pmid:26714822

    CrossRefPubMed
59. 59.↵
    2. Tang VM,
    3. Lang DJ,
    4. Giesbrecht CJ, et al

    . White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection. BMC Res Notes 2015;8:515 doi:10.1186/s13104-015-1501-5 pmid:26423806

    CrossRefPubMed
60. 60.↵
    2. McNutt M

    . Journals unite for reproducibility. Science 2014;346:679 doi:10.1126/science.aaa1724 pmid:25383411

    Abstract/FREE Full Text
61. 61.↵
    2. Collins FS,
    3. Tabak LA

    . Policy: NIH plans to enhance reproducibility. Nature 2014;505:612–13 doi:10.1038/505612a pmid:24482835

    CrossRefPubMedWeb of Science
62. 62.↵
    2. Papinutto ND,
    3. Maule F,
    4. Jovicich J

    . Reproducibility and biases in high field brain diffusion MRI: an evaluation of acquisition and analysis variables. Magn Reson Imaging 2013;31:827–39 doi:10.1016/j.mri.2013.03.004 pmid:23623031

    CrossRefPubMed
63. 63.↵
    2. Jones DK,
    3. Knösche TR,
    4. Turner R

    . White matter integrity, fiber count, and other fallacies: the do's and don'ts of diffusion MRI. Neuroimage. 2013;73:239–54 doi:10.1016/j.neuroimage.2012.06.081 pmid:22846632

    CrossRefPubMedWeb of Science
64. 64.↵
    2. Vollmar C,
    3. O'Muircheartaigh J,
    4. Barker GJ, et al

    . Identical, but not the same: intra-site and inter-site reproducibility of fractional anisotropy measures on two 3.0T scanners. Neuroimage 2010;51:1384–94 doi:10.1016/j.neuroimage.2010.03.046 pmid:20338248

    CrossRefPubMedWeb of Science
65. 65.↵
    2. Pfefferbaum A,
    3. Sullivan EV

    . Microstructural but not macrostructural disruption of white matter in women with chronic alcoholism. Neuroimage 2002;15:708–18 doi:10.1006/nimg.2001.1018 pmid:11848714

    CrossRefPubMedWeb of Science
66. 66.↵
    2. Pfefferbaum A,
    3. Sullivan EV,
    4. Hedehus M, et al

    . In vivo detection and functional correlates of white matter microstructural disruption in chronic alcoholism. Alcohol Clin Exp Res 2000;24:1214–21 doi:10.1111/j.1530-0277.2000.tb02086.x pmid:10968660

    CrossRefPubMedWeb of Science
67. 67.↵
    2. Ma L,
    3. Hasan KM,
    4. Steinberg JL, et al

    . Diffusion tensor imaging in cocaine dependence: regional effects of cocaine on corpus callosum and effect of cocaine administration route. Drug Alcohol Depend 2009;104:262–67 doi:10.1016/j.drugalcdep.2009.05.020 pmid:19595517

    CrossRefPubMed
68. 68.↵
    2. Tobias MC,
    3. O'Neill J,
    4. Hudkins M, et al

    . White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology 2010;209:13–24 doi:10.1007/s00213-009-1761-7 pmid:20101394

    CrossRefPubMed
69. 69.↵
    2. Bora E,
    3. Yücel M,
    4. Fornito A, et al

    . White matter microstructure in opiate addiction. Addict Boil 2012;17:141–48 doi:10.1111/j.1369-1600.2010.00266.x

    CrossRefPubMed
70. 70.↵
    2. Pagani E,
    3. Agosta F,
    4. Rocca MA, et al

    . Voxel-based analysis derived from fractional anisotropy images of white matter volume changes with aging. Neuroimage 2008;41:657–67 doi:10.1016/j.neuroimage.2008.03.021 pmid:18442927

    CrossRefPubMed
71. 71.↵
    2. Nusbaum AO,
    3. Tang CY,
    4. Buchsbaum MS, et al

    . Regional and global changes in cerebral diffusion with normal aging. AJNR Am J Neuroradiol 2001;22:136–42 pmid:11158899

    Abstract/FREE Full Text
72. 72.↵
    2. Haász J,
    3. Westlye ET,
    4. Fjær S, et al

    . General fluid-type intelligence is related to indices of white matter structure in middle-aged and old adults. Neuroimage 2013;83:372–83 doi:10.1016/j.neuroimage.2013.06.040 pmid:23791837

    CrossRefPubMed
73. 73.↵
    2. Malpas CB,
    3. Genc S,
    4. Saling MM, et al

    . MRI correlates of general intelligence in neurotypical adults. J Clin Neurosci 2016;24:128–34 doi:10.1016/j.jocn.2015.07.012 pmid:26455546

    CrossRefPubMed
74. 74.↵
    2. Ances BM,
    3. Roc AC,
    4. Korczykowski M, et al

    . Combination antiretroviral therapy modulates the blood oxygen level–dependent amplitude in human immunodeficiency virus–seropositive patients. J Neurovirol 2008;14:418–24 doi:10.1080/13550280802298112 pmid:19040188

    CrossRefPubMed
75. 75.↵
    2. Alter MJ

    . Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(1 suppl):S6–9 pmid:16352363

    CrossRefPubMedWeb of Science
76. 76.↵
    2. Bladowska J,
    3. Zimny A,
    4. Knysz B, et al

    . Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study. J Hepatol 2013;59:651–57 doi:10.1016/j.jhep.2013.05.008 pmid:23680314

    CrossRefPubMedWeb of Science
77. 77.↵
    2. Heaps-Woodruff JM,
    3. Wright PW,
    4. Ances BM, et al

    . The impact of human immune deficiency virus and hepatitis C coinfection on white matter microstructural integrity. J Neurovirol 2016;22:389–99 doi:10.1007/s13365-015-0409-0 pmid:26689572

    CrossRefPubMed
78. 78.↵
    2. Berlin JA,
    3. Santanna J,
    4. Schmid CH, et al

    ; Anti-Lymphocyte Antibody Induction Therapy Study Group. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002;21:371–87 doi:10.1002/sim.1023 pmid:11813224

    CrossRefPubMedWeb of Science
79. 79.↵
    2. Alexander AL,
    3. Lee JE,
    4. Lazar M, et al

    . Diffusion tensor imaging of the brain. Neurotherapeutics 2007;4:316–29 doi:10.1016/j.nurt.2007.05.011 pmid:17599699

    CrossRefPubMedWeb of Science
80. 80.↵
    2. Hong S,
    3. Banks WA

    . Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun 2015;45:1–12 doi:10.1016/j.bbi.2014.10.008 pmid:25449672

    CrossRefPubMed
81. 81.↵
    2. Anthony IC,
    3. Ramage SN,
    4. Carnie FW, et al

    . Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005;64:529–36 doi:10.1093/jnen/64.6.529 pmid:15977645

    CrossRefPubMed
82. 82.↵
    2. Moher D,
    3. Liberati A,
    4. Tetzlaff J, et al

    . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097 doi:10.1371/journal.pmed.1000097 pmid:19621072

    CrossRefPubMed